Adroit Market Research
Plasma Protease C1 Inhibitor Market By Drug Type (C1-Inhibitors, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist) Dosage Form (Lyophilized, Injectable) Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) and Forecast 2021 to 2028 Single Use License: US$ +1 (214) 884-6068
sales@adroitmarketresearch.com
4400
www.adroitmarketresearch.com
Request Sample
Adroit Market Research
Plasma Protease C1 Inhibitor Market Size and Share 2028 • The global plasma protease C1 inhibitor market is projected to reach USD 10,715.3 million by 2028, growing at a CAGR of 17.7%. Growing emphasis of biopharmaceutical companies on the development of effective therapies for treating various health disorders, increasing product consents and increasing research & development are some of the factors driving the growth of the global plasma protease C1 inhibitor market. • Adroit Market Research report on global Plasma protease C1 inhibitor market gives a holistic view of the market from 2018 to 2028, which includes factors such as market drivers, restraints, opportunities and challenges. The market has been studied for historic years from 2018 to 2019, with the base year of estimation as 2020 and forecast from 2021 to 2028. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the key players based on their product portfolio, geographic footprint, strategic initiatives and overall revenue. Prominent players operating in the global plasma protease C1 inhibitor market have been studied in detail.
+1 (214) 884-6068
sales@adroitmarketresearch.com
www.adroitmarketresearch.com
Adroit Market Research
Plasma Protease C1 Inhibitor Market Size and Share 2028 • The global plasma protease c1 inhibitor market is categorized based on drug type and dosage form. On the basis of drug type, the market is segmented into c1-inhibitors, kallikrein inhibitor and selective bradykinin b2 receptor antagonist. The C1inhibitors dominated the market in 2020. On the basis of dosage form, the market is segmented into lyophilized and injectable. • North America dominated the market for plasma protease C1 inhibitor in 2020, while Asia-Pacific is set to grow at the highest CAGR due to increasing R&D investments. Key players of the global plasma protease C1 inhibitor market include KalVista Pharmaceuticals, Inc., CSL Behring LLC, Lonis Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Pharming Technologies B.V., BioCryst Pharmaceuticals, Centogene AG, among others.
+1 (214) 884-6068
sales@adroitmarketresearch.com
www.adroitmarketresearch.com
Adroit Market Research
Plasma Protease C1 Inhibitor Market Size and Share 2028 • Key segments of the global plasma protease C1 inhibitor market • Drug Type Overview, 2018-2028 (USD Million) • C1-inhibitors
• Kallikrein inhibitor • Selective bradykinin b2 receptor antagonist
• Dosage Form 2018-2028 (USD Million) • Lyophilized • Injectable
+1 (214) 884-6068
sales@adroitmarketresearch.com
www.adroitmarketresearch.com
Adroit Market Research
About Us
Contact Us
Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a market’s size, key trends, participants and future outlook of an industry. We intend to become our clients’ knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code– Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps. Our analysts have tracked high growth markets in chemicals & materials, healthcare & pharmaceuticals, semiconductor & electronics, energy & power, food & retail, consumer goods, technology, and machinery & equipment sectors across the world to identify new opportunities, potential customers, prepare go-to-market (GTM) strategies, identify segments for revenue growth for companies, and many more.
US Headquarters 3131 McKinney Ave Ste 600 Dallas, TX 75204 ,U.S.A +1 (214) 884-6068
sales@adroitmarketresearch.com
Phone: +1 (214) 884-6068 Email: sales@adroitmarketresearch.com
www.adroitmarketresearch.com